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Mesoangioblasts are a class of adult stem cells of mesoderm 
origin, potentially useful for the treatment of primitive myopa-
thies of different etiology. Extensive in vitro and in vivo studies 
in animal models of muscular dystrophy have demonstrated 
the ability of mesoangioblast to repair skeletal muscle when 
injected intra-arterially. In a previous work we demonstrated 
that mesoangioblasts obtained from diagnostic muscle biopsies 
of IBM patients display a defective differentiation down skel-
etal muscle and this block can be corrected in vitro by transient 
MyoD  transfection.  We  are  currently  investigating  different 
pathways involved in mesoangioblasts skeletal muscle differ-
entiation and exploring alternative stimulatory approaches not 
requiring extensive cell manipulation. This will allow to obtain 
safe, easy and efficient molecular or pharmacological modula-
tion of pro-myogenic pathways in IBM mesoangioblasts. It is of 
crucial importance to identify factors (ie. cytokines, growth fac-
tors) produced by muscle or inflammatory cells and released in 
the surrounding milieu that are able to regulate the differentia-
tion ability of IBM mesoangioblasts. To promote myogenic dif-
ferentiation of endogenous mesoangioblasts in IBM muscle, the 
modulation of such target molecules selectively dysregulated 
would be a more handy approach to enhance muscle regenera-
tion compared to transplantation techniques.
Studies on the biological characteristics of IBM mesoangioblasts 
with their aberrant differentiation behavior, the signaling path-
ways possibly involved in their differentiation block and the pos-
sible strategies to overcome it in vivo, might provide new insights 
to better understand the etiopathogenesis of this crippling disor-
der and to identify molecular targets susceptible of therapeutic 
modulation.
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For  long  time,  satellite  cellshave  been  considered 
the only myogenic source for post-natal growth, repair 
and maintenance of skeletal muscle. More recently sev-
eral  blood-born  and  muscle-resident  stem  cells  have 
been identified in interstitial spaces of skeletal muscle 
with the capability to differentiate into myogenic cells, 
thus  contributing  to  de  novo  formation  of  muscle  fib-
ers (1-4). Mesoangioblasts are a new class of adult stem 
cells of mesoderm origin, potentially useful for the treat-
ment of primitive myopathies of different etiology (5). 
These cells, firstly isolated from dorsal aorta of murine 
embryos, have been largely studied in murine models, 
demonstrating their ability to extensively grow in vitro, 
maintaining their differentiation potential down the differ-
ent mesodermal tissues (smooth and skeletal muscle, fat 
and bone) (6,7). In addition, mesoangioblasts are capable 
to form muscle fibers after direct intramuscular injection 
and, more importantly, intra-arterial delivery into immune 
deficient dystrophic α sarcoglycan (αSG) null mice. In 
particular, by flowing through blood circulation they mi-
grate into downstream skeletal muscles, mainly reaching 
areas of muscle degeneration/regeneration, repairing skel-
etal muscle with concomitant recovery of global muscle 
function (8). The therapeutic value of mesoangioblasts in 
large animal models was recently demonstrated in a ca-
nine model of Duchenne muscular dystrophy (DMD) (9). 
Wild type (wt) or autologous mesoangioblasts transduced 
in vitro with a lentiviral vector expressing human microd-
ystrophin transplanted intra-arterially into dystrophic dogs 
led to extensive reconstitution of fibers expressing dys-
trophin, with improvement in the contraction force and, 
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in many cases, preservation of walking ability. This study 
showed that mesoangioblasts transplantation is a safe and 
effective procedure in large animals opening the way for 
possible future clinical trials in muscular disorders.
Human mesoangioblasts
In the last years, we and others isolated the human 
counterpart of murine mesoangioblasts from fragments of 
diagnostic muscle biopsies of patients affected by inflam-
matory myopathies (IM) (10), DMD (11) andfacioscapu-
lohumeral muscular dystrophy (FSHD) (12). These cells 
display a high proliferative rate and can be kept in culture, 
maintaining a normal diploid karyotype, up to 25 popula-
tion doublings (PD) when large senescent cells start to 
appear.
Human mesoangioblasts are able to differentiate into 
smooth and skeletal muscle, osteoblasts or adipocytes. 
When co-cultured with murine myogenic cells, exposed 
to muscle-differentiation medium (11) or cultured in nor-
mal human myoblasts-conditioned medium, to facilitate 
their commitment (10), a large proportion of cells differ-
entiate into multinucleated myotubes.
Human  cells  express  pericytes  markers  (annexin 
V;alkaline phosphatase, ALP; desmin; α-smooth actin, 
α-SMA; vimentin;platelet-derived growth factor recep-
tor β, PDGFR β), while, at variance with their murine 
counterpart, do not express typical endothelial markers 
(CD31, CD34 and VEGF receptor 2/KDR) and M-cadher-
in, NCAM, cytokeratins or neurofilaments. They do not 
constitutively express myogenic markers (MyoD, Myf5, 
Myogenin, Pax7). The expression of surface antigens is 
as follows: strongly positive for CD13 and CD44, weakly 
positive for CD49b, uniformly negative, among others, 
for CD31, CD34, CD45, CD133 (10, 11). Together, these 
markers identify human adult mesoangioblasts as the in 
vitro progeny of pericytes.
Mesoangioblasts from inflammatory myopathies
In our first study, we isolated with high efficiency 
and characterized mesoangioblasts from diagnostic mus-
cle biopsies of patients with idiopathic inflammatory my-
opathies (dermatomyositis, DM, polymyositis, PM and 
inclusion-body  myositis,  IBM).  Mesoangioblasts  from 
DM, PM and IBM retain the same proliferation ability 
and cell cycle distribution of cells isolated from normal 
muscle, and can be grown in vitro and expanded for as 
many as 25-30 passages (21,3 ± 3,21 PD), though not in-
definitely. The exposure of DM and PM mesoangioblasts 
to normal myoblast-conditioned medium is greatly effec-
tive in inducing skeletal muscle differentiation, outlining 
the importance of muscle-secreted factors for myogenic 
maturation of these stem cells. By contrast, IBM mesoan-
gioblasts display a marked and selective impairment of 
skeletal muscle differentiation, with the formation of only 
spare  mononucleated  myosin-positive  myotubes  under 
the same culture conditions promoting massive skeletal 
muscle differentiation of mesoangioblasts from DM, PM, 
and normal muscle. Of note, normal mesoangioblasts ex-
posed to IBM-myoblast-conditioned medium efficiently 
differentiate down skeletal muscle.
Interestingly, cultures of myogenic (satellite-derived) 
MyoD-positive cells obtained from the same biopsy sam-
ples undergo, under appropriate conditions, terminal dif-
ferentiation, indicating that the myogenic differentiation 
process can reach terminal stage in cultured satellite cells 
from IBM. This is in agreement with previous studies 
showing  that  cultured  IBM  myogenic  cells  proliferate 
and terminally differentiate and can be properly inner-
vated (13, 14).
Defective myogenic differentiation of IBM 
mesoangioblasts
We showed for the first time, that a progenitor cell, 
resident in a perivascular niche of IBM muscle is defec-
tive in myogenic determination and differentiation. No 
significant differences of age existed between the IBM 
and  DM/PM  patients  in  our  study,  excluding  a  mere 
consequence  of  muscle  aging,  but  strongly  suggesting 
a  causal  correlation  with  the  specific  pathophysiology 
of IBM. Interestingly, IBM muscle, that is characterized 
by an inadequate long term regeneration despite a nor-
mal number of satellite cells at least early in the disease, 
shows scarcity in muscle connective tissue of ALP-posi-
tive cells, likely activated pericytes (representing the cells 
from which mesoangioblasts are established in vitro), and 
a failure of the isolated mesoangioblasts to differentiate 
in vitro. Genome wide analysis of IBM mesoangioblasts 
showed that, differently from their normal or other my-
opathies counterparts, they express high levels of trans-
forming growth factor β 1 (TGFβ1), a known inhibitor 
of  myogenesis  (15),  SFRP  (Soluble  Frizzled  Related 
Protein) 2, a Wnt antagonist shown to block myogenic 
conversion of CD45+ SP cells (16), and BHLH (basic 
helix loop helix) B3, a transcription factor that inhibits 
MyoD activity (17), any of which might be responsible 
for the differentiation block. Unraveling the molecular 
basis of such block will likely provide both significant 
insights into the mechanisms of IBM muscle diminished 
regenerative potential involving satellite and other mus-
cle precursor cells, as well as more selective modulatory 
strategies to correct the defective myogenic maturation 
of IBM mesoangioblasts. However, we demonstrated that 
MyoD transient transduction is sufficient to induce a nor-
mal progression of IBM mesoangioblasts along the skel-
etal muscle differentiation path.R. Morosetti et al.
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Mesoangioblasts and inflammation in vivo
Analysis of molecular phenotype of human mesoan-
gioblasts from IM, although with specific differences in 
gene expression profiles between IBM and DM, shows 
a general up-regulation of several inflammation-related 
genes (10). This probably reflects a “conditioning” effect 
of  the  local  muscle  environment  in  immune-mediated 
myopathies characterized by marked increase of adhe-
sion molecules, chemokines and pro-inflammatory Th1 
cytokines. Mesoangioblasts expression of adhesion mol-
ecules involved in the processes of leukocytes rolling, ad-
hesion to vascular endothelium and transmigration across 
blood vessels well correlates with their ability, at variance 
with satellite cells, to migrate and home into damaged 
muscle by using their adhesion properties to reach inter-
stitial spaces of muscle when injected intra-arterially (8). 
Molecules such as integrins and selectins are highly ex-
pressed during muscle inflammation, as well as secreted 
factors such as stromal derived factor 1(SDF-1) and tu-
mor necrosis factor α (TNFα that have also a remarkable 
effect in improving homing to skeletal muscle of normal 
mouse and human mesoangioblasts (18).
IBM defective regeneration
Post-natal mesoangioblasts considered as part of the 
pericyte population are located in perithelial position and 
express ALP in vivo (11). It is interesting to note that a 
characteristic  histochemical  feature  of  PM  and  DM  is 
the strong ALP-positivity in perimysial and endomysial 
connective  tissue  (normally  connective  tissue  is ALP-
negative and only blood vessels’ wall and occasional re-
generant muscle fibers are stained), as opposed to IBM 
as well as other myopathies with increased connective 
tissue such as DMD, usually displaying no or very little 
ALP-positivity (19). It has been noted that this feature 
correlates more with the regenerative properties of mus-
cle rather than with inflammatory changes. In fact, ALP 
staining, usually negative earlier in the course of PM, 
persists  in  spite  of  immunosuppressive  treatment  that 
can rapidly eliminate inflammatory cells from the biopsy 
specimens, leading to the hypothesis that it could reflect 
activated or proliferating fibroblasts (19). Although ALP 
activity is generally considered a marker of osteoblasts 
differentiation, we showed data strongly suggesting that 
human  ALP-positive  mesoangioblasts  likely  represent 
an activated cell population found in the muscle connec-
tive tissue of IM, originating from the perivascular niche, 
susceptible of myogenic determination in vivo, as indi-
cated by MyoD expression and contributing to muscle 
repair and regeneration. To what extent mesoangioblasts 
contribute to muscle regeneration, either directly or by 
feeding  the  satellite  cells  pool,  is  unknown.  However, 
it is conceivable that during extensive muscle regenera-
tion, i.e. following inflammatory muscle damage as in 
DM-PM,  activated  mesoangioblasts  may  play  a  much 
more significant role than in normal muscle repair. On 
the contrary, in IBM muscle in spite of the presence of 
some degree of chronic lymphomonocytic inflammation, 
defective mesoangioblasts cannot keep up with progres-
sive muscle fibers degeneration participating to formation 
of new muscle fibers.
Ongoing studies
Our previous studies have shown that adenoviral-me-
diated overexpression of MyoD or silencing the inhibitor 
BHLHB3 gene by siRNA are able to restore the progres-
sion down the myogenic pathway of IBM mesoangiob-
lasts.  However,  though  experimentally  effective,  these 
procedures are unlike to be used in clinical practice as an 
induction treatment for autologous mesoangioblasts ex-
panded in culture before a possible intra-arterial delivery 
in IBM patients. Therefore we are currently investigating 
different pathways involved in skeletal muscle differen-
tiation of these cells and exploring alternative stimulatory 
approaches not requiring extensive cell manipulation, in 
order to obtain safe, easy and efficient molecular or phar-
macological  modulation  of  pro-myogenic  pathways  in 
IBM mesoangioblasts (20, 21).
Among the possible ex vivo treatments, we have ex-
plored in vitro the effects of different treatments with 
molecules  known  to  act  on  pro-myogenic  pathways, 
such as deacetylase inhibitors (DI, trichostatin A, TSA 
and  5-azacytidine)  as  single  agents  orin  combination 
with insulin-like growth factor 1 (IGF-1) and arginine-
vasopressin (AVP) that may enhance the response of IBM 
mesoangioblasts to DI. Transient exposure to DI or AVP 
followed by our differentiation protocol led to a signifi-
cant increase of myotubes formation, however, the effi-
ciency of these pharmacological approaches is not yet as 
good as that experimentally observed with MyoD overex-
pression (unpublished results). This implies that in order 
to become of clinical significance these treatments must 
be associated to others ex vivo approaches.
More recently, we have investigated the expression 
of the Rho family guanine nucleotide exchange factor 
(GEFT) known to be transcriptionally up-regulated dur-
ing myogenic differentiation, promoting, when overex-
pressed by gene transfer, skeletal muscle regeneration in 
vivo through the Rho-signaling cascade (22-25). In sev-
eral independent experiment, we have observed that IBM 
mesoangioblasts express significantly lower levels of the 
protein compared to normal or PM and DM mesoangiob-
lasts. By overexpressing GEFT in IBM mesoangioblasts, 
using a pCMV-Tag 2B expression vector containing the Mesoangioblasts of inclusion-body myositis
27
human GEFT cDNA sequence, upon exposure to differ-
entiating medium cells were able to fuse into multinu-
cleated myosin-positive myotubes, although with low ef-
ficiency. To determine whether IBM hGEFT-transduced 
mesoangioblasts  kept  their  myogenic  potential  also  in 
vivo, we transplanted them into the tibialis anterior of 
SCID mice and evaluated their ability to participate in 
muscle regeneration. From our in vivo experiments, we 
observed that after transplantation of GEFT-transfected 
IBM  mesoangioblasts,  many  areas  of  injected  muscle 
were reconstituted with fibers expressing human spectrin 
and containing human nuclei. Our data obtained so far, 
would suggest a possible functional role of GEFT in IBM 
muscle (manuscript in preparation).
Conclusions and future 
perspectives
Despite the presence also in IBM of CD8-mediated 
myocytotoxicity that is known to play a major role in PM, 
the exact pathogenic significance of inflammatory chang-
es in this disorder is unclear, as patients respond poorly 
or not at all to immunosuppressive therapies. In PM and 
in DM, the latter being a complement-mediated microan-
giopathy of skeletal muscle, current immunotherapies are 
usually effective and suppression of lymphomonocytic 
infiltration of muscle obtained by steroids and immune 
suppressive drugs is followed by efficient muscle regen-
eration and recovery of muscle strength and trophism. On 
the contrary, IBM muscle is characterized by the presence 
of unique degenerative features and inefficient regenera-
tive properties. Thus, IBM invariably progresses leading 
to a significant disability. Our studies showing that also 
from IBM it is possible to isolate cells with a high myo-
genic potential, such as mesoangioblasts, localized in the 
perivascular niche and normally not actively producing 
skeletal muscle, might open new therapeutic strategies of 
clinical relevance. However, since mesoangioblasts iso-
lated from IBM muscle fail to normally differentiate into 
skeletal muscle, in order to envisage a possible clinical 
use of autologous mesoangioblasts as muscle regenera-
tive cell therapy, it will be essential to stimulate in vitro 
IBM mesoangioblasts to enhance their defective myo-
genic differentiation. Even more important would be to 
successfully activate in vivo the endogenous mesoangiob-
lasts present in IBM muscle inducing them to make new 
regenerating fibers thus actively counteracting progres-
sive muscle degeneration. To this end, it is of paramount 
importance  the  identification  of  factors  (ie.  cytokines, 
growth  factors)  produced  by  muscle  or  inflammatory 
cells and released in the surrounding milieu able to regu-
late the differentiation ability of IBM mesoangioblasts. 
Modulation of such target molecules selectively dysregu-
lated in IBM muscle to promote myogenic differentiation 
of endogenous mesoangioblasts appears a more handy 
approach to enhance muscle regeneration compared to 
transplantation techniques.
Actually, the use of myogenic stem cells to cure any 
muscle disorder represents a very difficult challenge and 
it is now unpredictable whether it will ever come true. 
However, their safety as therapeutic tool has been demon-
strated (9) and a phase I clinical trial with donor-derived 
mesoangioblasts is ongoing in DMD patients (26). Nev-
ertheless, major technical problems exist that is necessary 
to overcome to achieve satisfactory transplantation and 
engraftment  of  homogeneous  population  of  myogenic 
precursors. On one side, in fact, in genetic myopathies 
it must be demonstrated that muscle reconstitution with 
fibers expressing the defective gene will be clinically rel-
evant to thwart progressive muscle weakness and degen-
eration. On the other side, in acquired diseases of muscle, 
transplanted stem cells might in turn become target of the 
same noxae causing the disease, thus frustrating the at-
tempt to significantly contribute to muscle regeneration 
and counteract the progressive atrophy of treated muscles. 
Nevertheless, studies on the biological characteristics of 
IBM mesoangioblasts with their aberrant differentiation 
behavior,  the  signaling  pathways  possibly  involved  in 
their differentiation block and the possible strategies to 
overcome it in vivo, might provide new insights to better 
understand the etiopathogenesis of this crippling disorder 
and to identify molecular targets susceptible of therapeu-
tic modulation.
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